Immunovant, Inc. (IMVT)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Immunovant, Inc. (IMVT)
Company Performance

Current Price

as of Oct 16, 2024

$29.17

P/E Ratio

N/A

Market Cap

$4.27B

Description

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Metrics

Overview

  • HQNew York, NY
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerIMVT
  • Price$29.17+2.17%

Trading Information

  • Market Cap$4.27B
  • Float42.37%
  • Average Daily Volume (1m)867,873
  • Average Daily Volume (3m)938,980
  • EPS-$1.92

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$87.15M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$94.20M
  • EV$3.30B
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B7.83
Documents
SEC Filings
8-K (2024-09-09)
8-K (2024-08-13)
8-K (2024-08-06)
8-K (2024-05-29)
8-K (2024-02-12)
8-K (2024-01-09)
8-K (2023-12-20)
8-K (2023-11-28)
8-K (2023-11-09)
8-K (2023-09-28)
8-K (2023-09-26)
8-K (2023-08-23)
8-K (2023-08-10)
8-K (2023-05-22)
8-K (2023-03-27)
8-K (2023-02-03)
8-K (2023-01-09)
10-Q (2024-08-06)
10-Q (2024-02-12)
10-Q (2023-11-09)
10-Q (2023-08-10)
10-Q (2023-02-03)
10-K (2024-05-29)
10-K (2023-05-22)
Earnings Calls
Earnings Report 2022Q4
Earnings Report (2022-06-09)
Factset Street Account
Immunovant upgraded to buy from neutral at UBS ($35.28, 0.00) (2023-10-13T08:07:46Z)
Immunovant reports Q2 EPS ($0.45) vs FactSet ($0.45) [14 est, ($0.58)-(0.30)] ($33.39, 0.00) (2023-11-09T12:01:55Z)
Immunovant announces results from 600 mg MAD cohort of phase 1 trial of IMVT-1402 in healthy adults; call at 8:00ET ($33.54, 0.00) (2023-11-28T12:03:47Z)